SUBSCRIBE
SUBSCRIBE

Phase I

Policy
Biopharma Update on the Novel Coronavirus: September 11
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 11, 2020.
September 10, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: September 9
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 9, 2020.
September 8, 2020
 · 
4 min read
 · 
BioSpace Editorial Staff
Use of AI in medical field.
Drug Development
AI in Medical Field for Clinical Trials Increase, Refining Endpoints, Quantifying Pain, & More
Ai in medical field is helping the researchers at clinical stage research by increasing the efficiency, refining endpoints and quantifying pain, and much more.
September 4, 2020
 · 
4 min read
 · 
Gail Dutton
Drug Development
Clinical Catch-Up: August 31-September 4
It was a busy week for both COVID-19-related clinical trial news and the rest of the industry. Here’s a look.
September 4, 2020
 · 
9 min read
 · 
Mark Terry
Pictured: A person performing a COVID-19 test/iSto
Drug Development
NanoViricides Outlines Two-Pronged Approach to Developing COVID-19 Therapies
NanoViricides, based in Shelton, Connecticut, outlined its approach to developing therapies against COVID-19 at the LD 500 investor conference yesterday.
September 4, 2020
 · 
3 min read
 · 
Mark Terry
Drug Development
Biopharma Update on the Novel Coronavirus: September 4
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 4, 2020.
September 3, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Courtesy of Willy Barton/Getty Images
Business
Sanofi, GSK Move COVID-19 Vaccine Candidate Into the Clinic, Expect Data by December
Months after forging a development partnership for a COVID-19 vaccine, GlaxoSmithKline and Sanofi are moving their adjuvanted vaccine candidate into the clinic.
September 3, 2020
 · 
2 min read
 · 
Alex Keown
Business
BioSpace Global Roundup, Sept. 3
Biopharma and life science companies from across the globe provide updates on their pipelines and businesses.
September 2, 2020
 · 
7 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: September 2
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 2, 2020.
September 1, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Policy
Biopharma Update on the Novel Coronavirus: August 31
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 31, 2020.
August 31, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Load More
PRESS RELEASES
Drug Development
HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC
May 1, 2024
 · 
2 min read
Drug Development
Micron Biomedical Announces The Lancet Publication of Positive Phase 1/2 Data From First Clinical Trial of Needle-Free Vaccines in Children
May 1, 2024
 · 
5 min read
Drug Development
Traverse Biotech Awarded Phase I SBIR Grant by the National Institute of Allergy and Infectious Diseases for Development of Innate Immune Stimulator
May 1, 2024
 · 
1 min read
Drug Development
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
May 1, 2024
 · 
6 min read
Drug Development
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
May 1, 2024
 · 
9 min read
Drug Development
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
May 1, 2024
 · 
5 min read
Drug Development
Nacuity Pharmaceuticals Announces First Patients Implanted in Final Cohort of Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression
April 30, 2024
 · 
3 min read
Drug Development
Arsenal Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of AB-2100 in Development as a Treatment for Clear-cell Renal Cell Carcinoma
April 30, 2024
 · 
3 min read
Drug Development
Aurion Biotech Announces Completion of Enrollment in Phase 1 / 2 Clinical Trial
April 30, 2024
 · 
3 min read
Drug Development
Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers
April 30, 2024
 · 
7 min read
Drug Development
Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005
April 30, 2024
 · 
3 min read
Drug Development
INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years
April 30, 2024
 · 
5 min read
Drug Development
Recce Pharmaceuticals Announces Safety Committee Approves High Dose of 4,000mg in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis
April 30, 2024
 · 
3 min read
Drug Development
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
April 30, 2024
 · 
4 min read
Drug Development
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
April 30, 2024
 · 
7 min read
Drug Development
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon
April 30, 2024
 · 
9 min read
Drug Development
MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic Diseases
April 30, 2024
 · 
4 min read
Drug Development
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
April 29, 2024
 · 
10 min read
Drug Development
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
April 29, 2024
 · 
2 min read
Drug Development
INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
April 29, 2024
 · 
6 min read
Load More